Clinical bottom line
Pediatric post-viral olfactory dysfunction (PVOD), including cases following COVID-19 infection, remains a challenging clinical entity with heterogeneous presentations and variable recovery trajectories. Recent evidence highlights that olfactory epithelial damage and central olfactory pathway involvement contribute to dysfunction. Emerging management strategies combining olfactory training with pharmacotherapy show promise, while non-pharmacologic interventions such as acupuncture warrant further study. Clinicians should adopt a cautious, individualized approach to diagnosis and treatment, recognizing the current limitations in robust pediatric-specific data.
What the evidence shows
Post-viral olfactory dysfunction in children is increasingly recognized, especially in the context of the COVID-19 pandemic. Kikuta et al. (2023) demonstrated heterogeneous damage to the olfactory epithelium in PVOD patients, suggesting that the degree and pattern of epithelial injury may influence recovery. Neuroimaging studies reveal that beyond peripheral epithelial damage, central olfactory structures including the olfactory bulb and tract can be affected. Philpott et al. (2022) and Kandemirli et al. (2021) used MRI and diffusion tensor imaging (DTI) to show alterations in olfactory bulb volume and tract integrity in post-viral anosmia, including COVID-19 cases, indicating a multifocal pathophysiology.
Management options remain limited but evolving. Hura et al. (2025) conducted a randomized controlled trial in a pediatric population with post-COVID-19 olfactory dysfunction, finding that structured olfactory training significantly improved olfactory function compared to controls. Morishita et al. (2026) reported additive benefits when combining free-choice olfactory training with pharmacotherapy, such as corticosteroids or vitamin A derivatives, in post-viral olfactory dysfunction, though their cohort was primarily adult and retrospective. Wilkinson et al. (2010) provided preliminary evidence supporting traditional Chinese acupuncture as a potential adjunctive therapy, though pediatric data are lacking and methodological limitations temper conclusions.
Caveats and uncertainty
The pediatric PVOD literature is limited by small sample sizes, heterogeneity in viral etiologies, and variable follow-up durations. Most neuroimaging studies focus on adults, and extrapolation to children must be cautious given developmental differences in olfactory system anatomy and plasticity. The randomized trial by Hura et al. (2025) is among the first pediatric-specific intervention studies but requires replication and longer-term outcome data. Pharmacologic interventions remain off-label in children, and safety profiles are not well established. The mechanisms underlying persistent dysfunction—whether predominantly peripheral, central, or both—are incompletely understood, complicating targeted therapy development.
How this may change practice
Clinicians should maintain a high index of suspicion for PVOD in children presenting with persistent olfactory complaints post-viral illness, including COVID-19. Early referral for olfactory testing and consideration of neuroimaging may help characterize the extent of dysfunction. Olfactory training emerges as a low-risk, accessible first-line intervention that can be initiated in pediatric patients, potentially augmented by pharmacotherapy in select cases after specialist consultation. Awareness of emerging adjunctive therapies such as acupuncture may inform multidisciplinary care, though these require further validation. Patient and family education regarding the variable prognosis and the importance of adherence to olfactory training protocols is essential.